BioStock: Oncoinvent’s CEO comments on Q3 and funding plans

The third quarter was a productive period for Oncoinvent, marked by significant milestones in the clinical development of the radiopharmaceutical Radspherin. Among other things, the company showcased clinical data for the candidate at two large congresses. To gear up for phase IIb in 2024, the company is now planning to raise capital. BioStock reached out to CEO Anders Månsson to find out more.

Read the full interview with Anders Månsson at biostock.se:

https://www.biostock.se/en/2023/10/oncoinvents-ceo-comments-on-q3-and-funding-plans/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/